Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China / 浙江大学学报(英文版)(B辑:生物医学和生物技术)
Journal of Zhejiang University. Science. B
;
(12): 948-954, 2020.
Article
in English
| WPRIM
| ID: wpr-880736
ABSTRACT
The aim of this study was to evaluate the safety of an antiviral regimen of protease inhibitors combined with Arbidol (umifenovir) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients. The genomic sequence of SARS-CoV-2 is highly homologous to that of SARS-CoV (Zhou et al., 2020). Previously published basic and clinical research on anti-SARS-CoV treatment found that lopinavir/ritonavir (LPV/r) could improve the prognosis of SARS patients (Chan et al., 2003; Chu et al., 2004). Darunavir (DRV) is another protease inhibitor that blocks the binding of SARS-CoV-2 to human angiotensin-converting enzyme 2 (Omotuyi et al., 2020). The broad-spectrum antiviral drug Arbidol (umifenovir) also shows in vitro anti-SARS-CoV activity (Khamitov et al., 2008).
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Protease Inhibitors
/
China
/
Retrospective Studies
/
Ritonavir
/
Drug Combinations
/
Lipid Metabolism
/
Lopinavir
/
Darunavir
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
Limits:
Adult
/
Female
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
English
Journal:
Journal of Zhejiang University. Science. B
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS